Posted by Michael Wonder on 05 May 2020
GeneTx and Ultragenyx announce GTX-102 granted fast track designation by US FDA for treatment of Angelman syndrome
4 May 2020 - GeneTx Biotherapeutics and Ultragenyx today announced that the U.S. FDA has granted fast track designation to GTX-102 for the treatment of Angelman syndrome.
GTX-102 is an investigational antisense oligonucleotide currently being evaluated in a Phase 1/2 study for the treatment of Angelman syndrome.
